Biomarin Pharmaceutical Inc (BMRN)

Receivables turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	2,830,220	2,731,722	2,563,532	2,443,023	2,373,030	2,261,604	2,184,719	2,123,138	2,059,481	1,999,471	1,903,678	1,871,615	1,827,451	1,829,463	1,891,778	1,815,339	1,822,817	1,822,364	1,813,337	1,772,797
Receivables	US$ in thousands	660,535	777,547	691,232	637,163	633,704	572,498	610,222	597,913	461,316	419,622	466,507	430,147	373,399	374,937	424,419	396,097	448,351	411,712	381,215	396,384
Receivables turnover		4.28	3.51	3.71	3.83	3.74	3.95	3.58	3.55	4.46	4.76	4.08	4.35	4.89	4.88	4.46	4.58	4.07	4.43	4.76	4.47

December 31, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $2,830,220K ÷ $660,535K
= 4.28

Biomarin Pharmaceutical Inc's receivables turnover ratio has shown fluctuations over the past few years, ranging from 3.51 to 4.89. The receivables turnover ratio measures how efficiently the company is collecting its accounts receivable during a specific period. A higher ratio typically indicates that the company is collecting its receivables more quickly.

From March 31, 2020, to December 31, 2022, the receivables turnover ratio remained relatively stable, fluctuating around the 4.00 mark. However, there was a notable decrease in the ratio from March 31, 2023, to September 30, 2024, where it ranged between 3.51 and 3.95. This decline may suggest a potential delay in collecting receivables during this period.

It is essential for Biomarin Pharmaceutical Inc to monitor its receivables turnover ratio consistently to ensure effective management of its accounts receivable. This analysis helps assess the company's liquidity and efficiency in converting credit sales into cash.